ZM447439, the Aurora kinase B inhibitor, suppresses the growth of cervical cancer SiHa cells and enhances the chemosensitivity to cisplatin

Journal of Obstetrics and Gynaecology Research

Volumn 37, Issue 6, 2011, Pages 591-600

  Zhang, Liya ^a   Zhang, Shulan ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Aurora B; Chemosensitivity; Cisplatin; SiHa cells; ZM447439

Indexed keywords

AURORA B KINASE; CISPLATIN; HISTONE H3; N [4 [6 METHOXY 7 (3 MORPHOLINOPROPOXY) 4 QUINAZOLINYLAMINO]PHENYL]BENZAMIDE; PROTEIN BCL 2; PROTEIN P53; VASCULOTROPIN;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE S PHASE; CHEMOSENSITIVITY; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG POTENTIATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PROTEIN EXPRESSION; UTERINE CERVIX CANCER; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; BENZAMIDES; CELL LINE, TUMOR; CISPLATIN; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FEMALE; HUMANS; MOLECULAR TARGETED THERAPY; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; QUINAZOLINES; UTERINE CERVICAL NEOPLASMS;

EID: 80052782931     PISSN: 13418076     EISSN: 14470756     Source Type: Journal    
DOI: 10.1111/j.1447-0756.2010.01414.x     Document Type: Article

References (25)

1. Sardi J, Sananes C, Giaroli A et al. Results of a prospective randomized trial with neoadjuvant chemotherapy in stage B bulky squamous carcinoma of the cervix. Gynecol Oncol 1993; 49: 156-165. (Pubitemid 23169984)
2. Carmena M, Earnshaw WC. The cellular geography of aurora kinases. Nat Rev Mol Cell Biol 2003; 4: 842-854. (Pubitemid 37411723)
3. Kimura M, Matsuda Y, Yoshioka T et al. Identification and characterization of STK12/Aik2: A human gene related to aurora of Drosphila and yeast IPL1. Cytogenet Cell Genet 1998; 82: 147-152. (Pubitemid 29002454)
4. Walsby E, Walsh V, Pepper C, Burnett A, Mills K. Effects of the aurora kinase inhibitors AZD1152-HQPA and ZM447439 on growth arrest and polyploidy in acute myeloid leukemia cell lines and primary blasts. Haematologica 2008; 93: 662-669. (Pubitemid 351669305)
5. Lee EC, Frolov A, Li R, Ayala G, Greenberg NM. Targeting Aurora kinases for the treatment of prostate cancer. Cancer Res 2006; 66: 4996-5002. (Pubitemid 43844918)
6. Lam AK, Ong K, Ho YH. Aurora kinase expression in col- orectal adenocarcinoma: Correlations with clinicopathologi- cal features,p16 expression, and telomerase activity. Hum Pathol 2008; 39: 599-604.
7. Scharer CD, Laycock N, Osunkoya AO et al. Aurora kinase inhibitors synergize with paclitaxel to induce apoptosis in ovarian cancer cells. J Transl Med 2008; 6: 79.
8. Tanaka S, Arii S, Yasen M et al. Aurora kinase B is a predictive factor for the aggressive recurrence of hepatocellular carcinoma after curative hepatectomy. Br J Surg 2008; 95: 611-619.
9. Park HS, Park WS, Bondaruk J et al. Quantitation of Aurora kinase A gene copy number in urine sediments and bladder cancer detection. J Natl Cancer Inst 2008; 100: 1401-1411.
10. Zhang XH, Rao M, Loprieato JA et al. Aurora A, Aurora B and survivin are novel targets of transcriptional regulation by histone deacetylase inhibitors in non-small cell lung cancer. Cancer Biol Ther 2008; 7: 388-397.
11. Rawson TE, Ruth M, Blackwood E et al. A pentacyclic aurora kinase inhibitor (AKI-001) with high in vivo potency and oral bioavailability. J Med Chem 2008; 51: 4465-4475.
12. DeMoe JH, Santaguida S, Daum JR, Musacchio A, Gorbsky GJ. A high throughput, whole cell screen for small molecule inhibitors of the mitotic spindle checkpoint identifies OM137, a novel Aurora kinase inhibitor. Cancer Res 2009; 69:1509-1516.
13. Guo J, Anderson MG, Tapang P et al. Identification of genes that confer tumor cell resistance to the Aurora B kinase inhibitor, AZD1152. Pharmacogenomics J 2009; 9: 90-102.
14. Hong YB, Kang HJ, Kim HJ et al. Inhibition of cell proliferation by a resveratrol analog in human pancreatic and breast cancer cells. Exp Mol Med 2009; 41: 151-160.
15. Ikezoe T, Yang J, Nishioka C et al. A novel treatment strategy targeting Aurora kinases in acute myelogenous leukemia. Mol Cancer Ther 2007; 6: 1851-1857. (Pubitemid 46954062)
16. Ditchfield C, Johnson VL, Tighe A et al. Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores. J Cell Biol 2003; 161: 267280. (Pubitemid 36529846)
17. Girdler F, Gascoigne KE, Eyers PA et al. Validating Aurora B as an anti-cancer drug target. J Cell Sci 2006; 119: 3664-3675. (Pubitemid 44501870)
18. Reiter R, Gais P, Jutting U et al. Aurora kinase A messenger RNA overexpression is correlated with tumor progression and shortened survival in head and neck squamous cell carcinoma. Clin Cancer Res 2006; 12: 5136-5141. (Pubitemid 44453341)
19. Jin ZJ. The sum of the combined drugs. Acta Pharmacol Sin 1980; 2: 70-76.
20. Twu NF, Yuan CC, Yen MS et al. Expression of Aurora kinase A and B in normal and malignant cervical tissue: High Aurora A kinase expression in squamous cervical cancer. Eur J Obstet Gynecol Reprod Biol 2009; 142: 57-63.
21. Takahashi M, Kigawa J, Minnagawa Y et al. Sensitivity to paclitaxel is not related to p53-dependent apoptosis in ovarian cancer cells. Eur J Cancer 2000; 36: 1863-1868. (Pubitemid 30639507)
22. Perego P, Giarola M, Righetti SC et al. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer Res 1996; 56: 556-562. (Pubitemid 26043653)
23. Long ZJ, Xu J, Yan M et al. ZM447439 inhibition of aurora kinase induces Hep2 cancer cell apoptosis in three- dimensional culture. Cell Cycle 2008; 7: 1473-1479. (Pubitemid 351872587)
24. Miyahara Y, Yoshida S, Motoyama S. Links effect of cis- diammine dichloroplatinum on vascular endothelial growth factor expression in uterine cervical carcinoma. Eur J Gynaecol Oncol 2004; 25: 33-39. (Pubitemid 38165917)
25. Montero E, Abreu C, Tonino P. Relationship between VEGF and p53 expression and tumor cellproliferation in human gastrointestinal carcinomas. J Cancer Res Clin Oncol 2008; 134: 193-201. (Pubitemid 350234064)